{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:53:33Z","timestamp":1792403613219,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003356","name":"Gazi University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003356","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["316213987"],"award-info":[{"award-number":["316213987"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["SFB 1278"],"award-info":[{"award-number":["SFB 1278"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["239748522"],"award-info":[{"award-number":["239748522"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["SFB1127"],"award-info":[{"award-number":["SFB1127"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.108997","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:03:45Z","timestamp":1758020625000},"page":"108997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Harnessing structure-activity relationships to repurpose the FLAP inhibitor BRP-7 into potent and selective sEH inhibitors"],"prefix":"10.1016","volume":"165","author":[{"given":"K\u00fcbra","family":"\u00c7al\u0131\u015fkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Karata\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"\u00c7al\u0131\u015fkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Werz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erden","family":"Banoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2025.108997_bb0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","article-title":"Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108997_bb0010","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.bbalip.2014.09.016","article-title":"Cyclooxygenase inhibitors: from pharmacology to clinical read-outs","volume":"1851","author":"Patrignani","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108997_bb0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bbalip.2014.08.012","article-title":"5-lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease","volume":"1851","author":"Radmark","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"3\u20134","key":"10.1016\/j.bioorg.2025.108997_bb0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10555-011-9315-y","article-title":"EET signaling in cancer","volume":"30","author":"Panigrahy","year":"2011","journal-title":"Cancer Metastasis Rev."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108997_bb0025","first-page":"C996","article-title":"Action of epoxyeicosatrienoic acids on cellular function","volume":"292","author":"Spector","year":"2007","journal-title":"Am. J. Phys. Cell Phys."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108997_bb0030","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2174\/092986710790827843","article-title":"Epoxyeicosatrienoic acid analogs and vascular function","volume":"17","author":"Sudhahar","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108997_bb0035","article-title":"Anti-inflammatory effects of epoxyeicosatrienoic acids","volume":"2012","author":"Thomson","year":"2012","journal-title":"Int J Vasc Med"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108997_bb0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/17460441.2014.881354","article-title":"Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases","volume":"9","author":"Duflot","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108997_bb0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1358\/dof.2009.34.7.1391872","article-title":"Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases","volume":"34","author":"Fang","year":"2009","journal-title":"Drugs Future"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108997_bb0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/1753-0407.12358","article-title":"Soluble epoxide hydrolase: a potential target for metabolic diseases","volume":"8","author":"He","year":"2016","journal-title":"J. Diabetes"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108997_bb0055","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/nrd2875","article-title":"Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases","volume":"8","author":"Imig","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108997_bb0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-030-50621-6_5","article-title":"Epoxy fatty acids are promising targets for treatment of pain, cardiovascular disease and other indications characterized by mitochondrial dysfunction, endoplasmic stress and inflammation","volume":"1274","author":"McReynolds","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bioorg.2025.108997_bb0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pharmthera.2017.06.006","article-title":"Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases","volume":"180","author":"Wagner","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108997_bb0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1021\/acs.jmedchem.0c01507","article-title":"Discovery of soluble epoxide hydrolase inhibitors from chemical synthesis and natural products","volume":"64","author":"Sun","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108997_bb0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/JPR.S241893","article-title":"Inhibition of the soluble epoxide hydrolase as an analgesic strategy: a review of preclinical evidence","volume":"14","author":"Wang","year":"2021","journal-title":"J. Pain Res."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108997_bb0080","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1021\/jm100691c","article-title":"1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, Pharmacokinetics, and Reduction of Inflammatory Pain","volume":"53","author":"Rose","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108997_bb0085","doi-asserted-by":"crossref","first-page":"1100524","DOI":"10.3389\/fpain.2022.1100524","article-title":"Soluble epoxide hydrolase inhibition alleviates chemotherapy induced neuropathic pain","volume":"3","author":"Takeshita","year":"2022","journal-title":"Front Pain Res (Lausanne)"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108997_bb0090","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jpain.2014.05.008","article-title":"Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy","volume":"15","author":"Wagner","year":"2014","journal-title":"J. Pain"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108997_bb0095","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1021\/acs.jmedchem.2c01996","article-title":"Structure-directed discovery of potent soluble epoxide hydrolase inhibitors for the treatment of inflammatory diseases","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2025.108997_bb0100","doi-asserted-by":"crossref","first-page":"18412","DOI":"10.1021\/acs.jmedchem.4c01766","article-title":"Discovery of orally active Phenylquinoline-based soluble epoxide hydrolase inhibitors with anti-inflammatory and analgesic activity","volume":"67","author":"Ding","year":"2024","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108997_bb0105","doi-asserted-by":"crossref","first-page":"9201","DOI":"10.1021\/acs.jmedchem.3c00831","article-title":"Design, synthesis, and pharmacological characterization of a potent soluble epoxide hydrolase inhibitor for the treatment of acute pancreatitis","volume":"66","author":"Musella","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108997_bb0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/bs.apha.2024.10.007","article-title":"Soluble epoxide hydrolase: mechanisms and therapeutic potential in psychiatric and neurological disorders","volume":"102","author":"Zhao","year":"2025","journal-title":"Adv. Pharmacol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108997_bb0115","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s13311-020-00854-1","article-title":"Pharmacological inhibition of soluble epoxide hydrolase as a new therapy for Alzheimer\u2019s disease","volume":"17","author":"Grinan-Ferre","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108997_bb0120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acsptsci.4c00629","article-title":"Novel soluble epoxide hydrolase inhibitor: toward regulatory preclinical studies","volume":"8","author":"Jarne-Ferrer","year":"2025","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108997_bb0125","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2353\/ajpath.2009.080544","article-title":"Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection","volume":"174","author":"Simpkins","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bioorg.2025.108997_bb0130","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.2147\/NDT.S210403","article-title":"Soluble epoxide hydrolase inhibition enhances anti-inflammatory and antioxidative processes, modulates microglia polarization, and promotes recovery after ischemic stroke","volume":"15","author":"Yeh","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108997_bb0135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2314085121","article-title":"Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase","volume":"121","author":"Kelly","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108997_bb0140","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1021\/acs.jmedchem.3c02245","article-title":"Discovery of the sEH inhibitor Epoxykynin as a potent kynurenine pathway modulator","volume":"67","author":"Dotsch","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108997_bb0145","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/0091270010397049","article-title":"Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects","volume":"52","author":"Chen","year":"2012","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108997_bb0150","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/bcp.12855","article-title":"Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor","volume":"81","author":"Lazaar","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108997_bb0155","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s12028-021-01398-8","article-title":"Randomized, placebo-controlled trial of soluble epoxide hydrolase inhibition in patients with aneurysmal subarachnoid hemorrhage","volume":"36","author":"Martini","year":"2022","journal-title":"Neurocrit. Care."},{"key":"10.1016\/j.bioorg.2025.108997_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2021.106604","article-title":"The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells","volume":"158","author":"Mashayekhi","year":"2022","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108997_bb0165","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/acs.jmedchem.0c01886","article-title":"Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an analgesic for neuropathic pain and for use as a nonaddictive opioid alternative","volume":"64","author":"Hammock","year":"2021","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108997_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70033","article-title":"Randomized, double-blind, phase 1a single-ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers","volume":"17","author":"Schmidt","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"23","key":"10.1016\/j.bioorg.2025.108997_bb0175","doi-asserted-by":"crossref","first-page":"17259","DOI":"10.1021\/acs.jmedchem.1c01331","article-title":"Structure-based Design of Dual Partial Peroxisome Proliferator-Activated Receptor gamma agonists\/soluble epoxide hydrolase inhibitors","volume":"64","author":"Lillich","year":"2021","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108997_bb0180","doi-asserted-by":"crossref","first-page":"13728","DOI":"10.1021\/acs.jmedchem.5c00552","article-title":"Structure-based design of PROTACS for the degradation of soluble epoxide hydrolase","volume":"68","author":"Schonfeld","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108997_bb0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1517\/17460441.2013.735228","article-title":"Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors","volume":"8","author":"Caliskan","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108997_bb0190","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1016\/j.ejmech.2011.08.009","article-title":"Pyrazol-3-propanoic acid derivatives as novel inhibitors of leukotriene biosynthesis in human neutrophils","volume":"46","author":"Caliskan","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108997_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200137","article-title":"Discovery and optimization of Piperazine urea derivatives as soluble epoxide hydrolase (sEH) inhibitors","volume":"17","author":"Capan","year":"2022","journal-title":"Chemmedchem"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108997_bb0200","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.ejmech.2008.10.039","article-title":"Synthesis and biological evaluation of 4,5-diphenyloxazolone derivatives on route towards selective COX-2 inhibitors","volume":"44","author":"Dundar","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108997_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114167","article-title":"Novel potent benzimidazole-based microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C4 synthase","volume":"231","author":"Ergul","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108997_bb0210","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acsomega.2c06936","article-title":"Benzoxazolone-5-urea derivatives as human soluble epoxide hydrolase (sEH) inhibitors, Acs","volume":"8","author":"Gur Maz","year":"2023","journal-title":"Omega"},{"key":"10.1016\/j.bioorg.2025.108997_bb0215","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jpba.2013.10.039","article-title":"Chromatographic separation and biological evaluation of benzimidazole derivative enantiomers as inhibitors of leukotriene biosynthesis","volume":"89","author":"Sardella","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108997_bb0220","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1016\/j.bmc.2012.04.048","article-title":"Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP)","volume":"20","author":"Banoglu","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108997_bb0225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bcp.2016.08.023","article-title":"BRP-187: a potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase\/5-lipoxygenase-activating protein (FLAP) complex assembly","volume":"119","author":"Garscha","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108997_bb0230","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ejmech.2018.03.045","article-title":"Identification of multi-target inhibitors of leukotriene and prostaglandin E2 biosynthesis by structural tuning of the FLAP inhibitor BRP-7","volume":"150","author":"Gur","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108997_bb0235","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.bmc.2014.03.001","article-title":"Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography","volume":"22","author":"Amano","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108997_bb0240","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.drudis.2021.05.017","article-title":"Computational insights into the known inhibitors of human soluble epoxide hydrolase","volume":"26","author":"Bzowka","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108997_bb0245","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.drudis.2015.04.005","article-title":"Successful generation of structural information for fragment-based drug discovery","volume":"20","author":"Oster","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.108997_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117510","article-title":"Phenyl-benzyl-ureas with pyridazinone motif: potent soluble epoxide hydrolase inhibitors with enhanced pharmacokinetics and efficacy in a paclitaxel-induced neuropathic pain model","volume":"290","author":"Lengerli","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108997_bb0255","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejmech.2016.07.004","article-title":"Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7","volume":"122","author":"Levent","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108997_bb0260","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/acs.jcim.5b00592","article-title":"Discovery of potent soluble epoxide hydrolase (sEH) inhibitors by pharmacophore-based virtual screening","volume":"56","author":"Waltenberger","year":"2016","journal-title":"J. Chem. Inf. Model."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108997_bb0265","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1124\/dmd.112.047555","article-title":"Predictability of metabolism of ibuprofen and naproxen using chimeric mice with human hepatocytes","volume":"40","author":"Sanoh","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108997_bb0270","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1021\/acs.jmedchem.0c02063","article-title":"Combined Cardioprotective and adipocyte Browning effects promoted by the Eutomer of dual sEH\/PPARgamma modulator","volume":"64","author":"Hartmann","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108997_bb0275","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0003-2697(88)90256-4","article-title":"Affinity purification of cytosolic epoxide hydrolase using derivatized epoxy-activated Sepharose gels","volume":"169","author":"Wixtrom","year":"1988","journal-title":"Anal. Biochem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108997_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103142","article-title":"Protocol for lipid mediator profiling and phenotyping of human M1- and M2-monocyte-derived macrophages during host-pathogen interactions","volume":"5","author":"Gunther","year":"2024","journal-title":"STAR Protoc"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108997_bb0285","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0378-4347(00)82742-5","article-title":"Separation of lipoxins and leukotrienes from human granulocytes by high-performance liquid chromatography with a radial-Pak cartridge after extraction with an octadecyl reversed-phase column","volume":"493","author":"Steinhilber","year":"1989","journal-title":"J. Chromatogr."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:31:12Z","timestamp":1762223472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825008776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":57,"alternative-id":["S0045206825008776"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108997","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing structure-activity relationships to repurpose the FLAP inhibitor BRP-7 into potent and selective sEH inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108997"}}